WO2023226822A1 - Procédé d'utilisation d'un dérivé d'azétidine pour traiter des infections virales et utilisation - Google Patents
Procédé d'utilisation d'un dérivé d'azétidine pour traiter des infections virales et utilisation Download PDFInfo
- Publication number
- WO2023226822A1 WO2023226822A1 PCT/CN2023/094492 CN2023094492W WO2023226822A1 WO 2023226822 A1 WO2023226822 A1 WO 2023226822A1 CN 2023094492 W CN2023094492 W CN 2023094492W WO 2023226822 A1 WO2023226822 A1 WO 2023226822A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- independently selected
- compound
- once
- patient
- Prior art date
Links
- 230000009385 viral infection Effects 0.000 title claims abstract description 15
- 208000036142 Viral infection Diseases 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title description 5
- 150000001539 azetidines Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 239000003814 drug Substances 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 239000002207 metabolite Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 229940002612 prodrug Drugs 0.000 claims abstract description 15
- 239000000651 prodrug Substances 0.000 claims abstract description 15
- 239000012453 solvate Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 208000025721 COVID-19 Diseases 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 241000711573 Coronaviridae Species 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 241001678559 COVID-19 virus Species 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 241000411851 herbal medicine Species 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 229940126585 therapeutic drug Drugs 0.000 claims description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 3
- 241000315672 SARS coronavirus Species 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004069 aziridinyl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 238000005399 mechanical ventilation Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 2
- 239000003154 D dimer Substances 0.000 claims description 2
- 102000008857 Ferritin Human genes 0.000 claims description 2
- 108050000784 Ferritin Proteins 0.000 claims description 2
- 238000008416 Ferritin Methods 0.000 claims description 2
- 230000037429 base substitution Effects 0.000 claims description 2
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 claims description 2
- 108010052295 fibrin fragment D Proteins 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 230000000153 supplemental effect Effects 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract description 2
- 230000010534 mechanism of action Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- -1 hexafluorophosphate Chemical compound 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 102100039683 Cyclin-G-associated kinase Human genes 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 102100038079 AP2-associated protein kinase 1 Human genes 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- 101000742699 Homo sapiens AP2-associated protein kinase 1 Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 7
- 238000004809 thin layer chromatography Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- ZSSKLIHICFDDPR-UHFFFAOYSA-N trimethyl-[2-[[4-(1h-pyrazol-4-yl)pyrrolo[2,3-b]pyridin-1-yl]methoxy]ethyl]silane Chemical compound C1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1C=1C=NNC=1 ZSSKLIHICFDDPR-UHFFFAOYSA-N 0.000 description 5
- DRANOGPOHXHUQP-UHFFFAOYSA-N 2-[(4-bromopyrrolo[2,3-b]pyridin-1-yl)methoxy]ethyl-trimethylsilane Chemical compound C1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1Br DRANOGPOHXHUQP-UHFFFAOYSA-N 0.000 description 4
- 102000015617 Janus Kinases Human genes 0.000 description 4
- 108010024121 Janus Kinases Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CKXWJAPUCSPQHF-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound N1C=CC=2C1=NC=CC=2C=1C=NN(C=1)C1(CN(C1)S(=O)(=O)CC)CC#N CKXWJAPUCSPQHF-UHFFFAOYSA-N 0.000 description 2
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 2
- LEZHTYOQWQEBLH-UHFFFAOYSA-N 4-bromo-1h-pyrrolo[2,3-b]pyridine Chemical compound BrC1=CC=NC2=C1C=CN2 LEZHTYOQWQEBLH-UHFFFAOYSA-N 0.000 description 2
- AEUAEICGCMSYCQ-UHFFFAOYSA-N 4-n-(7-chloroquinolin-1-ium-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;dihydrogen phosphate Chemical compound OP(O)(O)=O.ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 AEUAEICGCMSYCQ-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- MTDSWHCNFJPIKT-UHFFFAOYSA-N C(C)S(=O)(=O)N1CC(C1)(N1N=CC(=C1)C1=C2C(=NC=C1)N(C=C2)COCC[Si](C)(C)C)CC#N Chemical compound C(C)S(=O)(=O)N1CC(C1)(N1N=CC(=C1)C1=C2C(=NC=C1)N(C=C2)COCC[Si](C)(C)C)CC#N MTDSWHCNFJPIKT-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 239000004381 Choline salt Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004012 Tofacitinib Substances 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 229940051183 casirivimab Drugs 0.000 description 2
- 229960002328 chloroquine phosphate Drugs 0.000 description 2
- 235000019417 choline salt Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 150000005332 diethylamines Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097042 glucuronate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 108010028403 hemagglutinin esterase Proteins 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229940051184 imdevimab Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 229960004525 lopinavir Drugs 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- WIDKTXGNSOORHA-CJHXQPGBSA-N n,n'-dibenzylethane-1,2-diamine;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;tetrahydrate Chemical class O.O.O.O.C=1C=CC=CC=1CNCCNCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 WIDKTXGNSOORHA-CJHXQPGBSA-N 0.000 description 2
- 125000005487 naphthalate group Chemical group 0.000 description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940043131 pyroglutamate Drugs 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 229960000311 ritonavir Drugs 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000010333 shufeng jiedu Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 229960001350 tofacitinib Drugs 0.000 description 2
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 2
- 229960004626 umifenovir Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HQUIOHSYUKWGOM-UHFFFAOYSA-N 2-(1-ethylsulfonylazetidin-3-ylidene)acetonitrile Chemical compound CCS(=O)(=O)N1CC(=CC#N)C1 HQUIOHSYUKWGOM-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229940119498 AAK1 inhibitor Drugs 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 101710167605 Spike glycoprotein Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Definitions
- the present invention relates to the use of azetidine derivatives as Janus kinase (JAK) inhibitors in the treatment of viral infection-related diseases, particularly the use of azetidine derivatives as Janus kinase (JAK) inhibitors in the treatment of coronavirus. Use in diseases related to viral infections.
- JK Janus kinase
- Viral infection seriously threatens human health. Viruses can invade the body through multiple ways, such as respiratory tract infection, genitourinary system infection, and digestive tract infection, and proliferate in susceptible host cells. Viral infection is a process of interaction between the virus and the body, and between the virus and susceptible cells. Viral infection produces varying degrees of damage or viral diseases depending on the type of virus and individual differences in the human body.
- Coronaviruses are single-stranded RNA enveloped viruses, which are divided into four categories: ⁇ , ⁇ , ⁇ and ⁇ .
- the ⁇ category can be divided into four subgroups A-D. So far, 6 viral molecules (except SARS-CoV-2) have been discovered, each of which can cause different types of diseases.
- the main clinical manifestations are upper respiratory tract and gastrointestinal tract infections. SARS and MERS virus infections can cause pneumonia, kidney failure and other serious organ damage and death. According to statistics, the patient mortality rates caused by SARS and MERS are 9% and 36% respectively.
- Coronavirus particles are covered with a fatty membrane, and there are three types of glycoproteins on the membrane surface: spike glycoprotein (S protein, which is the receptor binding site, cell lysis and main antigenic site), small envelope glycoprotein ( E protein, Envelope protein, a smaller protein that binds to the envelope), M protein, Membrane protein, which is responsible for the transport of nutrients across the membrane and the budding of new viruses. release and formation of the viral envelope).
- S protein spike glycoprotein
- E protein Envelope protein, a smaller protein that binds to the envelope
- M protein Small envelope glycoprotein
- Membrane protein which is responsible for the transport of nutrients across the membrane and the budding of new viruses. release and formation of the viral envelope.
- the envelope of the beta group A coronavirus also has a shorter spike protein, namely hemagglutininesterase (HE protein).
- HE protein hemagglutininesterase
- N protein nulceocapsid phosphor protein
- a first aspect of the present invention provides compounds of formula (I), pharmaceutically acceptable salts, stereoisomers, polymorphs, solvates, metabolites or prodrugs thereof for the preparation of preventive and/or therapeutic Use in medicines for viral infections,
- R 1 is selected from C(O)R 8 and S(O) 2 R 9 ;
- R 2 is selected from H, CN, halogen and C 1-6 alkyl
- R 5 , R 6 and R 7 are each independently selected from H, halogen, CN, C 1-6 alkyl, C 1-6 alkoxy and C(O)NR 10 R 11 ;
- a third aspect of the present invention provides compounds of the above formula (I), pharmaceutically acceptable salts, stereoisomers, polymorphs, solvates, metabolites or prodrugs thereof, which are used for prevention and/or Treat related diseases caused by viral infections.
- R2 is selected from H, CN, F and methyl.
- R2 is selected from H and methyl.
- R 3 and R 4 are each independently selected from H, F, Cl and CN.
- R 3 and R 4 are H.
- R 5 , R 6 and R 7 are each independently selected from H, F, Cl, CN, methyl, ethyl, methoxy and C(O )NH 2 .
- R 5 is H, F, Cl, CN, methyl or C(O)NH 2 ;
- R 6 is H, Cl, CN, methyl or methoxy
- R 8 and R 9 are each independently selected from methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl group, tert-butyl, aziridinyl, pyrrolidinyl, phenyl, benzyl and N(CH 3 ) 2 , wherein each of the above groups is optionally selected from 1, 2 or 3 independently from F, CN Substituted with methyl substituents.
- each occurrence of R 10 and R 11 is independently selected from H, methyl and ethyl.
- the present invention provides compounds, pharmaceutically acceptable salts, stereoisomers, polymorphs, solvates, metabolites or prodrugs thereof in the preparation of compounds for the prevention and/or treatment of viral infections.
- said compound is selected from:
- the compound of formula (I) is:
- the pharmaceutically acceptable salts include selected from the group consisting of aspartate, bicarbonate/carbonate, bisulfate, borate, camphorsulfonate, citrate, cyclic Hexamethonate Salt, ethanesulfonate, ethanesulfonate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hydroiodide/iodide, isethyl sulfonate Acid, lactate, methyl sulfate, naphthylate, 2-naphthalene sulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, naphthalene Acid, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, glycosate, stearate, tannin, xinafoate, aluminum salt, arginine Salt, benza
- the virus is a coronavirus.
- the coronavirus is selected from any one of SARS-CoV-1, SARS-CoV-2, MERS, 229E, NL63, OC43, HKU1 or a combination thereof.
- the coronavirus is SARS-CoV-2.
- the medicine of the present invention also includes pharmaceutically acceptable excipients.
- the excipients include any one or a combination of two of excipients, diluents, carriers, flavoring agents, binders or fillers.
- the carriers include liposomes. , micelles, microspheres or microcapsules, etc.
- the dosage form of the medicine of the present invention includes tablets, capsules, granules, powders or injections.
- Each dosage form of medicine can be prepared according to conventional methods in the pharmaceutical field.
- the pharmaceutical dosage form of the present invention is a capsule.
- the pharmaceutical dosage form of the present invention is a capsule
- the capsule specifications i.e., the compound of formula I contained in each capsule, its pharmaceutically acceptable salts, stereoisomers, polymorphs form, solvate, metabolite or prodrug
- 0.1-50 mg such as 0.1-20 mg, e.g.
- 0.2-10 mg such as 0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg or 6 mg, such as 0.5 mg, 1 mg or 2 mg.
- the drug also includes one or more other therapeutic drugs.
- the one or more other therapeutic drugs are selected from one or more of antiviral drugs, hormonal drugs, immune drugs, anticoagulant drugs, Chinese herbal medicines, etc.
- the antiviral drugs include Imdevimab, Casirivimab, Monupivir, Remdesivir, Lopinavir, Ritonavir, Nematvir, Hydroxychloroquine, Chloroquine Phosphate, Azizumab One or more of vudine, alpha-interferon, ribavirin, arbidol, tofacitinib, etc.
- the hormonal drugs include corticosteroids and the like, such as methylprednisolone, dexamethasone and the like.
- the immune drugs include COVID-19 human immunoglobulin, tocilizumab, etc.
- the anticoagulant drug includes low molecular weight heparin, unfractionated heparin, etc.
- the Chinese herbal medicine includes one or more of Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Shufeng Jiedu Capsules, Qingfei Paidu Decoction, etc.
- the compound of formula (I), a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate, metabolite or prodrug thereof is present in an amount of less than about 100 nM, for example less than about 90 nM , 80nM, 70nM, 60nM, 50nM, 40nM, 30nM, 20nM, 19nM, 18nM, 17nM, 16nM, 15nM, 14nM, 13nM, 12nM, 11nM, 10nM or less inhibit AAK1 with IC50 .
- the compound of formula (I), a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate, metabolite or prodrug thereof is present in an amount of less than about 1000 nM, for example less than about IC50 inhibits GAK at 950nM, 900nM, 850nM, 800nM, 750nM, 700nM, 650nM, 600nM, 550nM, 500nM, 450nM, 400nM, 350nM, 340nM, 330nM, 320nM, 310nM, 300nM or less.
- the prevention and/or treatment includes administering to the patient a prophylactically or therapeutically effective amount of a compound of formula (I), its pharmaceutically acceptable salts, stereoisomers, polymorphs, solvents
- the compound, metabolite or prodrug is preferably administered at a daily dose of 0.0001-100mg/kg body weight, and the preferred dose is 0.0001-100mg/kg, 0.0001-90mg/kg, 0.0001-80mg/kg, 0.0001-70mg daily /kg, 0.0001-60mg/kg, 0.0001-50mg/kg, 0.0001-40mg/kg, 0.0001-30mg/kg, 0.0001-20mg/kg, 0.001-100mg/kg, 0.001-90mg/kg, 0.001-80mg/kg , 0.001-70mg/kg, 0.001-60mg/kg, 0.001-50mg/kg, 0.001-40mg/kg, 0.001-30mg
- the frequency of administration is once a day, twice a day, three times a day, once a week, once every two weeks, once every three weeks, once every four weeks, or once a month, once every five weeks, or once every six weeks.
- the dosing cycle is 1-200d, such as 3d, 4d, 5d, 6d, 7d, 8d, 9d, 10d, 11d, 12d, 13d, 14d, 21d, 28d, 60d, 90d, 180d.
- administration routes include oral administration, parenteral administration, and transdermal administration.
- the parenteral administration includes but is not limited to intravenous injection, subcutaneous injection, and intramuscular injection.
- a compound of formula (I), a pharmaceutically acceptable salt, stereoisomer, polymorph, solvate, metabolite or prodrug thereof is combined with one or more other therapeutic agents Combined administration.
- the one or more other therapeutic drugs are selected from one or more of antiviral drugs, hormonal drugs, immune drugs, anticoagulant drugs, Chinese herbal medicines, etc.
- the antiviral drugs include Imdevimab, Casirivimab, Monupivir, Remdesivir, Lopinavir, Ritonavir, Nematvir, Hydroxychloroquine, Chloroquine Phosphate, Azizumab One or more of vudine, alpha-interferon, ribavirin, arbidol, tofacitinib, etc.
- the hormonal drugs include corticosteroids and the like, such as methylprednisolone, dexamethasone and the like.
- the immune drugs include COVID-19 human immunoglobulin, tocilizumab, etc.
- the anticoagulant drug includes low molecular weight heparin, unfractionated heparin, etc.
- the Chinese herbal medicine includes one or more of Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Shufeng Jiedu Capsules, Qingfei Paidu Decoction, etc.
- the patient is a COVID-19 patient.
- the COVID-19 patients are asymptomatic, mild, common, severe, or critical patients.
- the COVID-19 patient is a hospitalized COVID-19 adult patient requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
- ECMO extracorporeal membrane oxygenation
- the COVID-19 patient has at least one elevated inflammatory marker, such as CRP, D-dimer, LHD, ferritin, etc.
- references to "or” herein mean the term “and/or” and may be used interchangeably with the term “and/or”.
- alkyl is defined to include saturated aliphatic hydrocarbons, including straight and branched chains.
- an alkyl group has 1 to 6, such as 1 to 4 carbon atoms.
- C 1-6 alkyl refers to a linear or branched group of 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl (isobutyl, sec-butyl, tert-butyl, n-pentyl or n-hexyl), which is optionally substituted by 1 or more (such as 1 to 3) suitable substituents such as halogen (e.g.
- C 1-4 alkyl refers to a linear or branched fat of 1 to 4 carbon atoms Family hydrocarbon chain (i.e. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
- alkoxy refers to a linear, branched or cyclic saturated monovalent hydrocarbon radical of the formula -O-alkyl, where the term “alkyl” is as defined above or as defined below "Cycloalkyl", such as methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, cyclobutoxy, pentyloxy, isopentyloxy or n-hexyloxy, or their isomers.
- cycloalkyl refers to a saturated or unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (e.g., monocyclic such as cyclopropyl, cyclobutyl, cyclopentyl, Cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or bicyclo, including spiro, fused or bridged systems (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[ 3.2.1]octyl or bicyclo[5.2.0]nonyl, decalinyl, etc.), which is optionally substituted by 1 or more (such as 1 to 3) suitable substituents.
- monocyclic such as cyclopropyl, cyclobutyl, cyclopentyl, Cyclohexyl, cycloheptyl, cyclooctyl,
- C 3-10 cycloalkyl refers to a saturated or unsaturated non-aromatic monocyclic or polycyclic (such as bicyclic) hydrocarbon ring of 3 to 10 ring-forming carbon atoms ( for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or bicyclo[1.1.1]pentyl), optionally substituted by 1 or more (such as 1 to 3) suitable substituents, for example methyl substituted cyclopropyl.
- 3-10 membered heterocyclyl groups have 3-10 carbon atoms and heteroatoms in the ring.
- Groups such as, but not limited to, oxiranyl, aziridinyl, azetidinyl, oxetanyl, tetrahydrofuranyl, dioxolyl ( dioxolinyl), pyrrolidinyl, pyrrolidonyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, Piperazinyl or trithianyl.
- aryl refers to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated pi electron system.
- C 6-14 aryl means an aromatic group containing 6 to 14 carbon atoms, such as phenyl or naphthyl.
- Aryl groups are optionally substituted with 1 or more (such as 1 to 3) suitable substituents.
- heteroaryl refers to a monovalent monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 8, 9, 10, 11, 12, 13 or 14 ring atoms, In particular 1 or 2 or 3 or 4 or 5 or 6 or 9 or 10 carbon atoms and it contains at least one heteroatom which may be the same or different (the heteroatom is for example oxygen, nitrogen or sulfur), and, additionally In each case it may be benzo-fused.
- the heteroaryl group is selected from the group consisting of thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiazolyl Diazolyl, etc. and their benzo derivatives; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and their benzo derivatives.
- aralkyl preferably means an aryl-substituted alkyl group, wherein said aryl and said alkyl are as defined herein.
- the aryl group may have 6 to 14 carbon atoms
- the alkyl group may have 1 to 6 carbon atoms.
- Exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, phenylpropyl, phenylbutyl.
- halo or halogen group is defined to include F, Cl, Br or I.
- substituted refers to one or more (e.g., one, two, three or four) hydrogens are replaced by a selection from the groups indicated, provided that the normal valencies of the atoms indicated in the present case are not exceeded and that said substitutions form stable compounds. Combinations of substituents and/or variables are permissible only if such combinations form stable compounds.
- the compounds of the invention may also contain one or more (eg one, two, three or four) isotopic substitutions.
- H can be in any isotopic form, including 1 H, 2 H (D or deuterium), and 3 H (T or tritium);
- C can be in any isotopic form, including 12 C, 13 C, and 14 C;
- O can be in any isotope form, including 16 O, 18 O, etc.
- stereoisomer means an isomer formed due to at least one asymmetric center.
- compounds with one or more (e.g., one, two, three or four) asymmetric centers they may give rise to racemates, racemic mixtures, single enantiomers, diastereomers Conformational mixtures and individual diastereomers.
- Certain individual molecules may also exist as geometric isomers (cis/trans).
- compounds of the present invention may exist as mixtures of two or more structurally distinct forms in rapid equilibrium (often referred to as tautomers).
- tautomers include keto-enol tautomers, phenol-ketone tautomers, nitroso-oxime tautomers, and imine-enamine tautomers. wait. It is to be understood that the scope of this application encompasses all such products in any proportion (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99 %) isomers or mixtures thereof.
- the present invention encompasses all possible crystalline forms or polymorphs of the compounds of the invention, which may be a single polymorph or a mixture of more than one polymorph in any proportion.
- pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, solvates, metabolites or prodrugs that, upon administration to a patient in need thereof, can directly or Compounds of the invention or metabolites or residues thereof are indirectly provided.
- Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof.
- Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include aspartate, bicarbonate/carbonate, bisulfate, borate, camphorsulfonate, citrate, cyclamate, ethylenedisulfonate, ethanesulfonate , fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hydroiodide/iodide, isethionate, lactate, methyl sulfate, Naphthylate, 2-naphthalene sulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/diphosphate Hydrogen salts, pyroglutamate, glycolates, stearates, tannins and xinofoate.
- Suitable base addition salts are formed from bases that form non-toxic salts. Examples include aluminum salts, arginine salts, benzathine penicillin salts, calcium salts, choline salts, diethylamine salts, diethanolamine salts, glycinate salts, lysine salts, magnesium salts, meglumine salts, ethanolamine salts, Potassium salt, sodium salt, tromethamine salt and zinc salt.
- the compounds of the invention may exist in the form of hydrates or solvates, wherein the compounds of the invention comprise as a structural element of the crystal lattice of the compound a polar solvent, in particular such as water, methanol or ethanol.
- a polar solvent in particular such as water, methanol or ethanol.
- the amount of polar solvent, especially water, may be present in stoichiometric or non-stoichiometric ratios.
- metabolites of the compounds of the invention ie compounds formed in the body upon administration of the drug.
- the prodrugs of the invention can be prepared, for example, by using certain groups known to those skilled in the art (e.g. "pro-moieties” as described in H. Bundgaard, Design of Prodrugs (Elsevier, 1985)) are produced by replacing the appropriate functional groups present in the compounds of formula I.
- pharmaceutically acceptable carrier refers to a diluent, adjuvant, excipient or vehicle that is administered with a therapeutic agent and is suitable for contact with humans and/or within the scope of reasonable medical judgment. Tissues from other animals without undue toxicity, irritation, allergic reactions, or other problems or complications commensurate with a reasonable benefit/risk ratio.
- compositions/medicines of the present invention include, but are not limited to, sterile liquids such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, Mineral oil, sesame oil, etc.
- Water is an exemplary carrier when the pharmaceutical composition is administered intravenously.
- Physiological saline and aqueous glucose and glycerol solutions may also be used as liquid carriers, particularly for injections.
- Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glyceryl monostearate, talc, sodium chloride, skimmed milk powder, glycerin, propylene glycol, water, Ethanol etc.
- the compositions may also, if desired, contain minor amounts of wetting agents, emulsifying agents, or pH buffering agents.
- Oral formulations may contain standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1990).
- the compounds/compositions/drugs of the present invention may act systemically and/or locally.
- they may be administered by suitable routes, for example by injection, intravenously, intraarterially, subcutaneously, intraperitoneally, intramuscularly or transdermally; or by oral, buccal, nasal, transmucosal, topical, Administered as an ophthalmic preparation or by inhalation.
- the compounds/compositions/medicaments of the invention may be administered in suitable dosage forms.
- the dosage forms include, but are not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, and aqueous suspensions. , injectable solutions, elixirs, syrups.
- terapéuticaally effective amount refers to an amount of a compound that, when administered, alleviates to a certain extent one or more symptoms of the condition being treated.
- Dosage regimens can be adjusted to provide the best desired response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dosage may be proportionally reduced or increased as the exigencies of the therapeutic situation indicate. It is noted that dosage values may vary depending on the type and severity of the condition to be alleviated, and may include single or multiple doses. It is further understood that, for any particular individual, specific dosage regimens should be adjusted over time according to the individual needs and the professional judgment of the person administering or supervising the administration of the compositions.
- the amount of a compound of the invention administered will depend on the individual being treated, the severity of the disorder or condition, the rate of administration, disposition of the compound, and the judgment of the prescribing physician. Generally speaking, the effective dose is about 0.0001 to about 50 mg per kg of body weight per day, for example, about 0.01 to about 10 mg/kg/day (single or divided administration). For a 70 kg person, this would add up to about 0.007 mg/day to about 3500 mg/day, for example about 0.7 mg/day to about 700 mg/day.
- dosage levels no higher than the lower end of the foregoing ranges may be sufficient, while in other cases, larger dosages may still be employed without causing any deleterious side effects, provided that the larger dosage is first
- the dose is divided into several smaller doses to be administered throughout the day.
- the content or amount of the compound of the present invention in the pharmaceutical composition/drug may be about 0.01 mg to about 1000 mg, suitably 0.1-500 mg, preferably 0.1-300 mg, more preferably 0.1-150 mg, particularly preferably 0.3-50 mg, such as 0.5 mg, 1mg, 1.5mg, 2mg, 4mg, 10mg, 25mg wait.
- treating means reversing, alleviating, inhibiting the disorder or condition to which such term applies or the progression of one or more symptoms of such disorder or condition, or Preventing such a disease or condition or one or more symptoms of such a disease or condition.
- Subject as used herein includes humans or non-human animals.
- exemplary human subjects include human individuals (referred to as patients) suffering from a disease, such as a disease described herein, or normal individuals.
- non-human animals include all vertebrates, such as non-mammals (such as birds, amphibians, reptiles) and mammals, such as non-human primates, domestic animals and/or domesticated animals (such as sheep, dogs , cats, cows, pigs, etc.).
- the terms "subject” and “patient” are used interchangeably herein.
- PaO 2 /FiO 2 should be corrected according to the following formula: PaO 2 /FiO 2 ⁇ [760/atmosphere (mmHg)].
- the structure of the compound is confirmed by nuclear magnetic resonance spectroscopy ( 1 H NMR) or mass spectrometry (MS).
- the reaction is monitored by thin layer chromatography (TLC) or LC-MS.
- TLC thin layer chromatography
- the developing solvent systems used are: methylene chloride and methanol system, n-hexane and ethyl acetate system, petroleum ether and ethyl acetate system.
- the eluent system includes: methylene chloride and methanol system and n-hexane and ethyl acetate system.
- reaction temperature is room temperature (20°C to 30°C).
- Reagents used in this application were purchased from Acros Organics, Aldrich Chemical Company Or companies like Tebo Chemical.
- Step 1 4-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (8b)
- Step 2 4-(1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b] Pyridine(8c)
- Step 3 2-(1-(ethylsulfonyl)-3-(4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2 ,3-b]pyridin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile (8d)
- Step 4 2-(3-(4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl) nitrogen Hetetane-3-yl)acetonitrile (8)
- AAK1 and GAK are activated, thereby mediating virus entry into cells.
- AAK1 and GAK Inhibitors prevent viruses from entering host cells.
- AAK1 kinase (Tag-tagged), GAK kinase (Tag-tagged), Eu-tagged anti-Tag antibody, Alexa 647 dye-labeled tracers, etc., are all from Thermo Fisher Scientific.
- compound 8 prepared in Example 1 and the control compound baricitinib were added to the 384-well plate respectively, so that the final concentrations were 10000nM, 3330nM, 1110nM, 370nM, 123nM, 41.2nM, 13.7nM, 4.57nM, and 1.52nM respectively. ,0.5nM.
- kinase buffer and kinase/Eu-labeled anti-Tag antibody mixture The final concentration of GAK kinase is 5nM.
- Alexa Tracer 236 labeled with 647 dye the final concentration is 100nM. After incubation at room temperature for 60 minutes, read using a fluorescence plate reader.
- the 0% substitution rate control well did not add any inhibitor.
- the GAK inhibitor Staurosporine was added to the 100% substitution rate control well.
- Compound 8 prepared in Example 1 was added to a 384-well plate to a final concentration of 10000 nM, 3330 nM, 1110 nM, 370 nM, 123 nM, 41.2 nM, 13.7 nM, 4.57 nM, 1.52 nM, and 0.5 nM. Then add kinase buffer and kinase/Eu-labeled anti-Tag antibody mixture. The final concentration of AAK1 kinase is 5nM. Then join Alexa 647 dye-labeled tracer Tracer222, the final concentration is 100nM. After incubation at room temperature for 60 minutes, read using a fluorescence plate reader.
- the 0% substitution rate control well did not add any inhibitor.
- the AAK1 inhibitor sunitinib was added to the 100% substitution rate control well.
- IDBS XFfit was used to perform curve fitting on the substitution rate (the results are shown in Figure 1), and the IC 50 value of compound 8 for inhibiting kinase AAK1 was calculated to be 11.5nM.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne le traitement d'infections virales, en particulier d'infections à coronavirus. Plus précisément, l'invention concerne un composé de formule I, un sel pharmaceutiquement acceptable, un stéréoisomère, un polymorphe, un solvate, un métabolite ou un promédicament de celui-ci, ou l'utilisation d'une composition le comprenant dans la préparation d'un médicament pour le traitement d'infections virales. La présente invention a un mécanisme d'action clair, une efficacité claire et une bonne inocuité, et offre davantage d'options de médication pour des patients.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210595841 | 2022-05-26 | ||
CN202210595841.6 | 2022-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023226822A1 true WO2023226822A1 (fr) | 2023-11-30 |
Family
ID=88918357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/094492 WO2023226822A1 (fr) | 2022-05-26 | 2023-05-16 | Procédé d'utilisation d'un dérivé d'azétidine pour traiter des infections virales et utilisation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023226822A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017097224A1 (fr) * | 2015-12-11 | 2017-06-15 | 四川科伦博泰生物医药股份有限公司 | Dérivé d'azétidine, son procédé de préparation et son utilisation |
WO2019090143A1 (fr) * | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Analogues de pyrrolo[2,3-b]pyrimidine-5-carboxylate de pyrazolyle et leurs procédés de préparation |
-
2023
- 2023-05-16 WO PCT/CN2023/094492 patent/WO2023226822A1/fr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017097224A1 (fr) * | 2015-12-11 | 2017-06-15 | 四川科伦博泰生物医药股份有限公司 | Dérivé d'azétidine, son procédé de préparation et son utilisation |
WO2019090143A1 (fr) * | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Analogues de pyrrolo[2,3-b]pyrimidine-5-carboxylate de pyrazolyle et leurs procédés de préparation |
Non-Patent Citations (4)
Title |
---|
CHEN, CHONGXIANG ET AL.: "JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis", LEUKEMIA, vol. 35, 14 May 2021 (2021-05-14), XP037553405, DOI: 10.1038/s41375-021-01266-6 * |
ELY E WESLEY, RAMANAN ATHIMALAIPET V, KARTMAN CYNTHIA E, DE BONO STEPHANIE, LIAO RAN, PIRUZELI MARIA LUCIA B, GOLDMAN JASON D, SAR: "Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial", THE LANCET. RESPIRATORY MEDICINE, ELSEVIER, OXFORD, vol. 10, no. 4, 11 February 2022 (2022-02-11), Oxford , pages 327 - 336, XP093111621, ISSN: 2213-2600, DOI: 10.1016/S2213-2600(22)00006-6 * |
LIMEN RONAL YOSUA, SEDONO RUDYANTO, SUGIARTO ADHRIE, HARIYANTO TIMOTIUS IVAN: "Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis", EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, FUTURE DRUGS, LONDON, GB, vol. 20, no. 3, 4 March 2022 (2022-03-04), GB , pages 425 - 434, XP009550818, ISSN: 1478-7210, DOI: 10.1080/14787210.2021.1982695 * |
STEBBING JUSTIN; PHELAN ANNE; GRIFFIN IVAN; TUCKER CATHERINE; OECHSLE OLLY; SMITH DAN; RICHARDSON PETER: "COVID-19: combining antiviral and anti-inflammatory treatments", THE LANCET INFECTIOUS DISEASES, ELSEVIER, AMSTERDAM, NL, vol. 20, no. 4, 27 February 2020 (2020-02-27), AMSTERDAM, NL , pages 400 - 402, XP086103993, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(20)30132-8 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220339161A1 (en) | Compounds and compositions for treating hematological disorders | |
JP5913400B2 (ja) | 核内受容体結合剤 | |
AU2008209581B2 (en) | Nuclear receptor binding agents | |
US20200054594A1 (en) | Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof | |
JP2021165286A (ja) | グルタミナーゼ阻害剤の結晶形態 | |
WO2020259528A1 (fr) | Procédé de traitement de la fibrose pulmonaire idiopathique | |
US20180162837A1 (en) | Non-selective kinase inhibitors | |
CZ289629B6 (cs) | 2,4-Disulfonyl-alfa-fenyl-terc.butylnitron, jeho soli, farmaceutická kompozice s jeho obsahem a pouľití | |
TW201306842A (zh) | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 | |
TW401297B (en) | Treatment and prophylaxis of osteoporosis | |
JP2014520897A (ja) | 一酸化ルテニウム放出分子およびその使用 | |
CN116322663A (zh) | Ampk激活剂及其使用方法 | |
WO2023226822A1 (fr) | Procédé d'utilisation d'un dérivé d'azétidine pour traiter des infections virales et utilisation | |
CZ175396A3 (en) | 6-(2-imidazolinylamino)quinoline compounds usable as alpha-2 adrenoceptor agonists | |
US20070004777A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
WO2022017412A1 (fr) | Méthode de traitement d'une maladie du greffon contre l'hôte provoquée par une transplantation de cellules souches hématopoïétiques | |
WO2019047826A1 (fr) | Dérivé aromatique, son procédé de préparation, et ses applications médicales | |
WO2020221274A1 (fr) | Méthode de traitement de la toux à l'aide d'un composé de diaminopyrimidine | |
WO2023041024A1 (fr) | Procédé de traitement d'infections virales | |
US20230226196A1 (en) | Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use | |
TWI343258B (en) | Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative | |
CN117304242A (zh) | 烟酰胺单核苷酸衍生物及其在治疗和预防红细胞病症中的用途 | |
WO2024051795A1 (fr) | Dérivé de purinone substitué utilisé en tant qu'inhibiteur de la protéase spécifique de l'ubiquitine | |
WO2024112397A1 (fr) | Polythérapies comprenant des inhibiteurs de kras et des inhibiteurs de sph2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23810895 Country of ref document: EP Kind code of ref document: A1 |